Sarepta Therapeutics Stock Analysis (NASDAQ:SRPT)
Sarepta Therapeutics Analysis Video
View Sarepta Therapeutics stock analysis video. This is our SRPT analyst opinion covering the buy and sell arguments for SRPT stock.
Sarepta Therapeutics Inc Stock Rating (1/5)
Our Sarepta Therapeutics stock opinion is based on fundamentals of the company. This Sarepta Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.
Should you buy SRPT stock?
- Sarepta Therapeutics has a lower debt burden than its peers in the Medical sector, with a debt/equity ratio of 0.05.
Should you sell SRPT stock?
- Sales declined by -35.1% annually over the last 5 years.
- Sarepta Therapeutics posted an average Net loss of -4931% in the last twelve months.
- A negative ROE of -99.5% indicates that the company is not able to generate profits with the money shareholders have invested.
- The company has a negative free cash flow margin of -388.2%.